Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Single-tablet pioglitazone combination filed in Japan

This article was originally published in Scrip

Executive Summary

Takedahas filed an approval submission in Japan for a single-tablet combination of pioglitazone and metformin. The product stands to become the first fixed dose combination for type 2 diabetes in Japan, where pioglitazone, a thiazolidinedione, is already marketed alone as Actos. The single-tablet combination was approved as Actoplus met in the US this August and approved in the EU (as Competact) in July 2007. Japanese filings for Actos as concomitant therapy with either metformin or insulin were made in January and June respectively last year.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC030388

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel